- SCYNEXIS (SCYX +1.4%) has completed the enrollment of 455 subjects in a second Phase 3 clinical trial, VANISH-306, evaluating ibrexafungerp, a broad spectrum antifungal, for the treatment of women with vaginial yeast infections.
- A sister Phase 3, VANISH-303, was successful.
- Assuming a positive outcome from the second study, it expects to file a U.S. marketing application in H2.
Scynexis completes enrollment in second pivotal study of ibrexafungerp
Recommended For You
About SCYX Stock
Related Stocks
Symbol | Last Price | % Chg |
---|---|---|
SCYX | - | - |
SCYNEXIS, Inc. |